Clinical Trial Update: 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate [Phase 2]

View source ↗

Summary

A 24-week Phase 2 trial of VX-509 (an oral JAK3 inhibitor) in rheumatoid arthritis patients taking methotrexate has completed, including an open-label extension…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VX-509

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED